Shi Wei Ru Xiang pill alleviates acute gouty arthritis through suppressing NLRP3 inflammasome activation

Na Wang, Puchen Zhao, Qin Yin, Lizi Li, H. Eric Xu, Can Yang, Yanbei Tu, Yanfang LiFrontiers in Pharmacology 2025 · DOI

Abstract

This is the first study to comprehensively elucidate the therapeutic effects and underlying mechanisms of the Shi Wei Ru Xiang pill (SWR) against acute gouty arthritis (AGA) by inhibiting NLRP3 inflammasome activation. The results strongly indicate that SWR could serve as a promising anti-inflammatory medicine with an acceptable safety profile for the treatment of AGA and other inflammatory disorders linked to NLRP3 inflammasome activation.

Introduction

Acute gouty arthritis (AGA) is a debilitating inflammatory condition characterized by intense pain and joint swelling, triggered by the deposition of monosodium urate (MSU) crystals. The central driver of this inflammatory response is the NLRP3 inflammasome, a multi-protein complex that, upon activation, facilitates the maturation and release of pro-inflammatory cytokines such as IL-1β and induces pyroptosis. While conventional treatments like colchicine and non-steroidal anti-inflammatory drugs (NSAIDs) are effective, their long-term use is often hampered by significant gastrointestinal, hepatic, and renal toxicities.

The Shi Wei Ru Xiang pill (SWR) is a traditional Tibetan medicine that has been used for centuries to treat "Huang-shui disease," which corresponds clinically to AGA. Despite its historical use, the precise molecular mechanisms and active chemical constituents of SWR remained largely uncharacterized until this study.

Methods and Chemical Profiling

Researchers employed an integrated "network-to-molecule" approach to demystify SWR's efficacy. Chemical profiling was conducted using UPLC-Q-Exactive Orbitrap MS, which identified 58 distinct compounds within the formulation.

UPLC-MS chromatograms of SWR in negative (A) and positive (B) ionization modes, identifying 58 chemical components.

To evaluate the biological effects, the study utilized:

  • In Vitro Models: Human THP-1 cells stimulated with LPS and various NLRP3 triggers (Nigericin, MSU, ATP).
  • In Vivo Models: A rat model of MSU-induced AGA to assess joint swelling, gait, and organ toxicity.
  • Target Validation: Molecular docking and Isothermal Dose-Response Cellular Thermal Shift Assay (ITDR-CETSA) were used to confirm direct binding between SWR components and the NLRP3 protein.

Key Insights: Dual-Phase Inhibition

A significant finding of this research is that SWR inhibits the NLRP3 inflammasome at two distinct stages:

  1. Priming Phase: SWR suppresses the NF-κB signaling pathway, preventing the initial "readying" of the cell for inflammation.
  2. Activation/Assembly Phase: SWR prevents the oligomerization of ASC, a critical step in the physical assembly of the inflammasome complex.

This dual-action mechanism makes SWR particularly potent compared to agents that only target a single phase of the inflammatory cascade.

Results and Safety Profile

The study pinpointed three specific phenolic compounds—dehydrocostus lactone (DCL), gallic acid (GA), and 4-hydroxybenzoic acid (4-HBA)—as the primary drivers of NLRP3 inhibition. In cell cultures, SWR dose-dependently suppressed IL-1β production and caspase-1 activity.

Graphical abstract illustrating the therapeutic mechanism of SWR in treating acute gouty arthritis by inhibiting the NLRP3 inflammasome and its comparative safety.

In the rat model, SWR significantly reduced the arthritis index and ankle swelling. Notably, while the positive control drug colchicine effectively reduced inflammation, it also induced markers of renal and hepatic stress. In contrast, SWR-treated rats exhibited a superior safety profile, showing protective effects on the liver and kidneys. Furthermore, SWR treatment led to a significant decrease in serum uric acid (UA) levels.

Conclusion

This study provides the first comprehensive pharmacological evidence for the use of SWR in treating AGA. By identifying the active constituents and the dual-phase inhibition of the NLRP3 inflammasome, the researchers have validated a traditional remedy through modern scientific rigor. SWR emerges as a promising, safer alternative to current frontline gout medications, particularly for patients requiring long-term management or those with pre-existing organ sensitivities.

Summary updated

Abstract

This is the first study to comprehensively elucidate the therapeutic effects and underlying mechanisms of SWR against AGA by inhibiting NLRP3 inflammasome activation. This study strongly indicated that SWR could serve as a promising anti-inflammatory medicine with an acceptable safety profile for the treatment of AGA and other inflammatory disorders linked to NLRP3 inflammasome activation.
BibTeX
@inproceedings{wang2025shi,
  author = {Na Wang and Puchen Zhao and Qin Yin and Lizi Li and H. Eric Xu and Can Yang and Yanbei Tu and Yanfang Li},
  title = {{Shi Wei Ru Xiang pill alleviates acute gouty arthritis through suppressing NLRP3 inflammasome activation}},
  booktitle = {Frontiers in Pharmacology},
  year = {2025},
  doi = {10.3389/fphar.2025.1595578},
}
Figure